Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Samantha Hocking

A/Prof Samantha Hocking

Tirzepatide Compared to Semaglutide for Treatment of Obesity – Latest Evidence

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Genitourinary Syndrome of Menopause – Mythbusting for GPs

Prof Sonia Grover

Prof Sonia Grover

Dysmenorrhoea in Teens

Prof Paul Griffin

Prof Paul Griffin

Winter Virus Preparations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023